There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vanda (VNDA – Research Report) and Vigil ...

Vanda Pharmaceuticals Inc (VNDA) reports a 23% revenue increase in Q3 2024, driven by Fanapt sales, despite a net loss and ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript November 6, 2024 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.

Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Vanda (VNDA – Research Report) today and set a price target of $13.00. The company’s shares closed yesterday at $4.89. Duncan covers ...

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), a commercial-stage biopharmaceutical firm ...

WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $5.3 million in its third quarter. The Washington-based company said it had a loss of 9 cents per ...

View Vanda Pharmaceuticals Inc. (VNDA) current and estimated P/E ratio data provided by Seeking Alpha.

Hello, and thank you for standing by. At this time, I would like to welcome you to the Q3 2024 Vanda Pharmaceuticals Inc. Earnings Conference Call. All lines has been placed on mute to prevent any ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...